Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of ...

SpringWorks Therapeutics Inc. (NASDAQ:SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks Therapeutics announced that the European Medicine Agency’s Committee for ...

SpringWorks Therapeutics' drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of $29,000 for a 30-day supply, the company ...

Contacts. BeiGene Contacts: Investors Kevin Mannix +1 857-302-5189 [email protected] Media Kathleen Cuca +1 551-222-6790 [email protected] SpringWorks Contacts: Kim Diamond Vice President ...

Springworks is not an ordinary farm. Founded in 2014 by 19-year-old Trevor Kenkel, Springworks grows lettuce and raises fish in a complex, closed system of circulating water.

SpringWorks Therapeutics, Inc. , the Stamford, Conn.,-based biotech that launched its initial public offering ("IPO") in September 2019, raising ~$186 via the issuance of 10.35m shares priced at ...

SpringWorks launched last year with $103 million in financing, led by Bain Capital, OrbiMed Advisors and Pfizer Inc., and a plan to develop treatments for patients who lack good treatment options.